Slides
Page 1
Investor Presentation Q2 FY27 Result PI Industries Limited CDR India PI Industries Ltd.
Page 2
Agenda 2 01 Consolidated Financial Performance 02 Key Updates 03 Business Model & Strategy 04 ESG Initiatives 05 Awards & Recognition Agenda 01 Consolidated Financial Performance 02 Key Updates 03 Business Model & Strategy 04 ESG Initiatives 05 Awards & Recognition
Page 3
Our Biological engine delivering growth with Domestic outshining while sector headwinds impact exports … FINANCIALS Q2FY27 (Consolidated) 1 7 ,018 2,36 2 Q2 Health Sciences revenue grew 20% Trade working Capital reduced by 18 days 9 % 57% 1,222 70 % Q2 Biologicals • Global +250% • Domestic +45% Revenue EBITDA INR Mn PAT AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL 3 Q2 Domestic grew 19% Standalone Q2FY27: Revenue 12% : EBITDA 51% : PAT 58% H1 FY27 (Consolidated) 34 ,041 6, 05 5 10% 43% 3 ,664 55 % Q2 Agchem Exports declined 18% • Lower demand • Genericization • Pricing pressure FINANCIALS / KEY UPDATES / BUSINESS MODEL / ESG / AWARDS Our Biological engine delivering growth with Domestic outshining while sector headwinds impact exports FINANCIALS Lower demand Genericizotion Health Scien enue grew 2 Trade working Capital reduced by 18days
Page 4
• Agchem exports decline by~18% • Focus on volume growth post genericization through price optimisation • Cost escalation not actively passed through under current market conditions • Domestic revenue grew by ~19% • Biologicals grew aggressively 45%+ • Expanding crop reach & product portfolio • Health Sciences revenue grew by 20% • Commenced commercial GMP manufacturing of Galidesivir (API) • Global biologicals grew by +250% • US, Brazil & Mexico expanding channels & portfolio • Aggressive investments in product development by on - field trials & customer connect • Gross Margin impacted by • Higher Input cost (5%) • Pricing pressure due to El Nino & genericization • Overheads increased due to • Continued investments in Development of new businesses (6%) & R&D (2%) • New molecule launch expenses (1%) besides increase in energy cost (3%) Q2FY27 : Agility drove better performance of Domestic Brands & Biologicals; Exports impacted due to lower demand & cost escalation.. 16.7 % 19.0% 70.1 % 56.5% INR Mn Q2FY26 Q2FY27 Revenue 18,723 17,018 Gross Margin 57% 49% Overheads 5,306 6,091 EBITDA 5,434 2,36 2 EBITDA Margin % 29% 14% Net Profit 4,093 1,222 4 Q2FY26 Exports Revenue Domestic Revenue Q2FY27 EBITDA PAT Q2FY26 Q2FY27 14,739 3,984 5 ,434 4,093 12,277 4,741 2,36 2 1,222 AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL Q1FY27 17,023 57% 5,984 3,693 22% 2,442 FINANCIALS / KEY UPDATES / BUSINESS MODEL / ESG / AWARDS Q2FY27: Agility drove better performance of Domestic Brands & Biologicals; Exports impacted due to lower demand & cost escalation .. INRMn Q2FY26 Revenue 18,723 Gross Margin 57% Overheads 5,306 EBITDA 5,434 EBITDA Margin% 29% Net Profit 4,093 T 16.7% ..A. 79.0% 14,739 12,277 I 3,984 4,741 I Exports Revenue Domestic Revenue Q2FY26 ■ Q2FY27 ,.,,. --, QlFY27 Q2FY27 ' 17,023 17,018 57% 49% 5,984 6,091 3,693 2,362 22% 14% 2,442 1,222 '...,. __________ .,,., T 56.5% T 70. 7% 5,434 4,093 2,362 I 1,222 ■ EBITDA PAT Q2FY26 ■ Q2FY27 I Agchem exports decline by-18% Focus on volume growth post genericization through price optimisation Cost escalation not actively passed through under current market conditions Domestic revenue grew by-19% Biologicals grew aggressively 45%+ Expanding crop reach & product portfolio Health Sciences revenue grew by 20% Commenced commercial GMP manufacturing of Galidesivir (API) Global biologicals grew by +250% US, Brazil & Mexico expanding channels & portfolio Aggressive investments in product development by on-field trials & customer connect Gross Margin impacted by Higher Input cost (5%) Pricing pressure due to El Nino & genericization Overheads increased due to Continued investments in Development of new businesses {6%) & R&D (2%) New molecule launch expenses (7%) besides increase in energy cost (3%)
Page 5
• Agchem exports decline by~15% due to • Soft demand and pricing pressure from genericization in global agrochemical industry • 3 molecules commercialized • Domestic revenue grew by ~12% despite pricing pressure • Biologicals grew aggressively 55%+ • 2 products launche d • Health Sciences revenue de - grew by 4% • Continue to expand portfolio with new commercialization • Global Biologicals grew by +96% • Gross Margin impacted by • Higher input cost ( 3 %) • Pricing pressure H1 FY27 : Domestic demand and Biologicals momentum strengthen amid continued pricing pressure in Global Agrochemical sector... 1 5 . 0 % 11.6 % 54.7% 43.2% INR Mn H1FY26 H1FY27 Revenue 37,728 34,041 Gross Margin 57% 53% Overheads 11,029 12,076 EBITDA 10,653 6,05 5 EBITDA Margin % 28% 18% Net Profit 8,093 3,664 5 H1FY26 Exports Revenue Domestic Revenue H 1FY27 EBITDA PAT H 1FY26 H 1FY27 30,359 7 ,369 10,653 8,093 25,819 8,222 6,05 5 3,664 AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL FINANCIALS / KEY UPDATES / BUSINESS MODEL / ESG / AWARDS Hl FY27: Domestic demand and Biologicals momentum strengthen amid continued pricing pressure in Global Agrochemical sector ... INRMn Revenue Gross Margin Overheads EBITDA EBITDA Margin% Net Profit T 1s.0% .... 11.6% 30,359 25,879 I 7,369 8,222 ■ Exports Revenue Domestic Revenue HlFY26 ■ HlFY27 ,, ....... HlFY26 ' HlFY27 ' 37,728 34,041 - 57% 53% 11,029 12,076 10,653 6,055 28% 18% 8,093 3,664 , ... ___________ , T 43.2% T 54.7% 70,653 8,093 6,055 I 3,664 ■ EBITDA PAT HlFY26 ■ HlFY27 Agchem exports decline by-15% due to Soft demand and pricing pressure from genericization in global agrochemical industry 3 molecules commercialized Domestic revenue grew by -12% despite pricing pressure Biologicals grew aggressively 55%+ 2 products launched Health Sciences revenue de-grew by 4% Continue to expand portfolio with new commercialization Global Biologicals grew by +96% Gross Margin impacted by Higher input cost (3%) Pricing pressure
Page 6
Balance sheet Sep - 25 Mar - 26 Sep - 26 Shareholders Fund 1,08,269 1,12,305 1,14,574 Non Current Liabilities 5 ,044 4 ,365 4,353 Short term debt 3 55 893 696 Other Current Liabilities 6 ,067 7,136 7,684 Total 1,19,735 1,24,699 1,27,307 Fixed Asset Inc. Goodwill 50 ,530 56,496 60, 145 Non current investments & other assets 2 ,677 2 ,994 2, 626 Working Capital 23 ,713 25,628 22, 647 Cash, Bank & Investments 39,114 35,094 37,478 Other assets 3,701 4,487 4, 411 Total 1,19,735 1,24,699 1,27,307 Key Ratios (%) Annualised Debt/ Equity Ratio 0.02 0.02 0.02 Net Sales to Net Fixed Assets 1.69 1.33 1.2 6 Balance Sheet strength and cash surplus support our long - term moats; positions us well to navigate volatility and future investments 66 66 Inventory DIO Trade Receivables DSO 126 117 5 3 6 2 Payables DPO 139 121 NWC Days Q4FY26 Q2FY27 • Net Working Capital reduced by 18 Days ( 139 days in Mar 26 to 121 days in Sep - 26) releasing INR 2 , 9 81 Mn cash. • Surplus cash net of Debt is INR 35,737 Mn • Total capex for H1 FY27 stood at INR 5, 674 Mn , reflecting continued investment in efficiencies, capacities, new initiatives and R&D. AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL 6 INR Mn FINANCIALS / KEY UPDATES / BUSINESS MODEL / ESG / AWARDS Balance Sheet strength and cash surplus support our long-term moats; positions us well to navigate volatility and future investments Balance sheet Shareholders Fund Non Current Liabilities Short term debt Other Current Liabilities Fixed Asset Inc. Goodwill Non current investments & other assets Working Capital Cash, Bank & Investments Other assets Key Ratios (%) Annualised Debt/ Equity Ratio Net Sales to Net Fixed Assets Sep-25 1,08,269 5,044 355 6,067 50,530 2,677 23,713 39,114 3,701 0.02 l.69 Mar-26 l,12,305 4,365 893 7,736 56,496 2,994 25,628 35,094 4,487 0.02 7.33 , -, , \ ' Sep-26 1,14,574 4,353 696 7,684 60,145 2,626 22,647 37,478 4,411 0.02 7.26 Net Working Capital reduced by 18 Days ( 139 days in Mar 26 to 121 days in Sep-26) releasing INR 2,981 Mn cash. Surplus cash net of Debt is INR 35,737 Mn Total capex for HlFY27 stood at INR 5,674 Mn, reflecting continued investment in efficiencies, capacities, new initiatives and R&D. Inventory D10 66 66 Q4FY26 ■ Q2FY27 Trade Receivables D50 726 777 Payables DPO 53 62 NWC Days 739 INRMn 727
Page 7
7 1995 2020 2025 1961 2030 Reported Revenue CAGR Leading Agri Distribution player Unique approach of partnership with global innovators ~20% Top 5 Global CSM player • First to commence Agchem CSM • Pioneered Biologicals in India • R&D Investment ~20% Innovation led Agsciences • Chemical and Biological product innovation and solution • Geographical expansion: US, LATAM, Mexico and UK ~20% Agsciences - > Lifesciences • Focus on Biological offerings • Bringing PI ’ s novel innovation to markets globally. • Foray into specialty and electronics chemicals • Pharma CRDMO PI Story: From AgSciences to LifeSciences driven by Innovation & Partnership Transformation at each stage Consistent Revenue Growth AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL Right to win Innovation mindset Global partnership Strong Balance sheet Execution excellence
Page 8
Transforming into a Lifesciences Company Biologicals Biostimulants, biocontrol and plant - nutrition solutions NCEs in Agchem Novel, patented crop - protection molecules from in - house discovery Specialty & Electronic Chemicals High - purity chemicals for semi conductor and electronic markets Pharma CRDMO Contract research, development and manufacturing for pharma PI leveraging opportunities & unique approaches to build robust moats ; Investments taking shape 8 1 2 3 4 A Global Technology play Global Innovator Niche process technology Differentiated business model AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL Biologicals A Global Technology play Biostimulants, biocontrol and plant-nutrition solutions NCEs in Agchem Global Innovator Novel, patented crop protection molecules from in-house discovery ..... .. .. .. .. .. .. Specialty& Electronic Chemicals Niche process technology High-purity chemicals for semi conductor and electronic markets Pharma CRDMO Differentiated business model Contract research, development and manufacturing for pharma Pl leveraging opportunities & unique approaches to build robust moats ; Investments taking shape
Page 9
Biologicals : Technology based platform creating a global impact * • Q2 FY27 Revenue growth of 250% + • World ’ s 1 st Biological foliar application nematicide commercialized in Mexico and the US • Harpin αβ commercialized in 23 countries • 4.7M acres covered globally • Product development in Brazil, Mexico, Europe & the US: • 900+ field trials, 1,000+ growers • Strengthening relationships with key influencers and stakeholders 9 Market & product development investment up 108% Expanded our Distribution network by 3x in Brazil, Mexico and Spain; building US Midwest network R&D investment up 102% (H1 FY27 v/s H1 FY26) to strengthen peptide discovery and development Brazil: label expansions in Corn & Cotton for 2 products (Teikko & Saori) UK: Relaunched ProAct US: 3 peptides state - registered for 2027 launch; Launching 5 brands ( Saori, ProAct, PREdefender,Physera & Ataliol ) Biostimulants Biocontrol 1 *Excludes India AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL . • . -~ Biostimulants Biocontrol /t.:i ~ Teikko J!, Sha Nema · (#PLANT Pl LIN ~ Moshy'" Market & product development investment up 108% Expanded our Distribution network by 3x in Brazil, Mexico and Spain; building US Midwest network R&D investment up 102% (Hl FY27 v/s Hl FY26) to strengthen peptide discovery and development US: 3 peptides state-registered for 2027 launch; Launching 5 brands ( Saari, ProAct, PREdefender,Physera & Ataliol) Brazil: label expansions in Corn & Cotton for 2 products (T eikko & Saari) UK: Relaunched ProAct
Page 10
v 1 st Indian company to innovate “ P IOXANILIPROLE ” R&D platform delivering global innovative products State - of - the - art R&D Labs at 4 locations NABL ISO17025 and GLP certified New ICP - OES Addition of UPLC - CAD (Charged Aerosol Detector) 50 + projects a t different development stages 700+ Scientists incl. 200+ Doctorates R&D 265+ Patents t ill date w ith 13 patents in H1FY27 In - house library with a vast array of knowledge resources 10 AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL 2 Pipeline roadmap Pioxaniliprole Launched in India Global launch in focused geographies ( post regulatory approvals) Next wave 2– 3 molecules in advanced stages from Chemical and Bio segment. Offers opportunity for global partnership . 10 2 FINANCIALS / KEY UPDATES / BUSINESS MODEL / ESG / AWARDS R&D platform delivering global innovative products State-of-the-art R&D Labs at 4 locations 700+ Scientists incl. 200+ Doctorates 265+ Patents till Pipeline roadmap NABL IS017025 and GLP certified New ICP-OES Addition of UPLC-CAD (Charged Aerosol Detector) 50+ projects at different development stages In-house library with a vast array of knowledge resources Pioxaniliprole Launched in India
Page 11
Pioxazon ® : India ’ s first discovered molecule ; Launched in India Segment: Insecticide | Formulation: 20% SC | IRAC Group 28 (RRA) Target crops & pests RICE Yellow Stem Borer MAIZE FAW More crops targeted for label expansion BENGAL GRAM Pod borer Why Pioxaniliprole ? HIGHEST EFFICACY Against target pest s LONGEST DURATION OF CONTROL Maximum availability in the plant system FASTER ABSORPTION Within 30 minutes SAFEST For beneficial insects 200+ LPDs +5400 + 1 Lac Scientists from KVK, State agriculture universities and Central Institutes 1700+ Large Plot Demos - Tested Across India. Proven Across Diverse Field Conditions as per farmer practice . Approved and tested by Progressive farmer s Channel Partner Footfall at Pioxazon Fields LPTs 1200+ Large Plot Trials - Scientifically tested. AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL 2 Pre-Development 11 2 FINANCIALS / KEY UPDATES / BUSINESS MODEL / ESG / AWARDS Pioxazon : India s first discovered molecule; Launched in India Segment: Insecticide I Formulation: 20% SC I IRAC Group 28 (RRA) Target crops & pests 0 RICE G MAIZE • BENGAL GRAM Borer FAW Pod borer More crops targeted for label expansion Pre-Development LPTs 1200+ Large Plot Trials - Scientifically tested. LPDs +5400 Large Plot Demos- Tested Across India. Proven Across Diverse Field Conditions as per farmer practice. ~+llac Approved and tested by Progressive farmers Why Pioxaniliprole? 0 HIGHEST EFFICACY I Against target pests 0 LONGEST DURATION OF CONTROL I Maximum availability in the plant system 0 FASTER ABSORPTION I Within 30 minutes 0 SAFEST For beneficial insects eJll 1700+ Channel Partner Footfall at Pioxazon Fields I ~ 200+ Scientists from KVK, State agriculture universities and Central Institutes
Page 12
v CSM : Building differentiated manufacturing capabilities through process innovation & technology 6 0+ molecules are currently in active pipeline with > 6 0% in advanced stages of development 20 molecules have been commercialized over the last few years… will drive significant future growth Ramp - up in Pipeline from Diversified Segments . Non - Agchem ’ s share in new enquiries has increased by 75 % Diversifying Portfolio with new segments like Electronic & Specialty Chemicals.. 12 AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL • Successfully onboarded global customers • Commercialized 3 specialty/ electronic chemical molecules • Applications including semiconductors, electronics and specialty chemica l • Dedicated EC Kilo Lab commercialization by Q3 FY27 3 Successfully on boarded global customers Commercialized 3 specialty/electronic chemical molecules Applications including semiconductors, electronics and specialty chemical Dedicated EC Kilo Lab commercialization by Q3 FY27
Page 13
Health Sciences: Differentiated business model … • Investment in infrastructure for future growth • Kilo Lab plant in Lodi, Italy • State of the art R&D Center, Hyderabad • AIFA GMP Certification and QC Lab GMP Certification for Lodi Site • On boarded marquee customers including large pharma companies strengthening differentiated capabilities. • Working on two strategic products for long term contracts 13 INR Mn Q2FY26 Q2FY27 % YOY Revenue 634 759 20% PBT * (654) ( 63 3 ) INR Mn H1FY26 H1FY27 % YOY Revenue 1,357 1,301 (4)% PBT * (1,236) ( 1,2 50 ) * Post intercompany eliminations 4 Lodi, Italy R&D Center, Hyderabad Jaipur AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL INRMn Q2FV26 Q2FY27 %YOY Pi 634 759 20% (654) (633) INRMn HlFY26 HlFY27 %YOY 1,357 1,301 (4)% (1,236) (1,250) * Post intercom pony eliminations Lodi, Italy
Page 14
Long - term growth outlook remains intact... Continued focus & investment for long - term sustainable growth … Margin discipline, scaling platforms. Exports: Technology focused approach to drive new business es Domestic: Focus on portfolio diversification and product reach Health Science: Building a differentiated business model Long term investments deliver global innovative products • Major crop prices firmed up showing a positive trend • Biological business continues to gain traction • Differentiated portfolio, crop reach and new launches to drive growth • Extreme climate impact creating uncertainties of outcomes while long term growth trajectory remains intact • PI has built from concept - to - market a robust pipeline of innovation as a platform to drive chem - bio solutions • Development investments in Pioxazon ® to build farmer’ s confidence on performance in the short term to enable mid term scale and market acceptance • Partnering deeper with innovators to build a stronger core by value addition, creating a strong outlook • Expect acceleration of growth through new products; 5+ to be commercialized in FY27 • Non - Agchem opportunities with differentiated technologies to build long term competitive moats • Continued focus on volume growth amidst cost optimization & escalations • Deepening engagement with customers showing some early shoots • Building dedicated development and manufacturing capacities; Infrastructure coming to mature phase in Lodi, Italy • Actively working on strategic products for long term contracts AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL 14 R& D : Technology based platform creating impact at global scale Biologicals : • PI’ s Uniqu e PREtec precision peptide platform showing excellent results leading to high adaption • Driv ing growth through market expansions, product development for newly launched brands • Taking differentiated approach for development of geograph ica l and crop expansion … Margins to normalize once volatility subsides … FINANCIALS / KEY UPDATES / BUSINESS MODEL / ESG / AWARDS Continued focus & investment for long-term sustainable growth l;:I. Domestic: ii& Focus on portfolio diversification and product reach llf. A~ Exports: ._"'Ji/f, Technologyfocused approach to drive new businesses [][][) Biologicals: Technology based platform creating impact at global scale [][][) R&D: Long term investments deliver global innovative products ~ Health Science: 1!.111 Building a differentiated business model I I I Major crop prices firmed up showing a positive trend Biological business continues to gain traction Differentiated portfolio, crop reach and new launches to drive growth Extreme climate impact creating uncertainties of outcomes while long term growth trajectory remains intact Partnering deeper with innovators to build a stronger core by value addition, creating a strong outlook Expect acceleration of growth through new products; 5+ to be commercialized in FY27 Non-Agchem opportunities with differentiated technologies to build long term competitive moats Continued focus on volume growth amidst cost optimization & escalations Pl s Unique PREtec precision peptide platform showing excellent results leading to high adaption Driving growth through market expansions, product development for newly launched brands Ta king differentiated approach for development of geographical and crop expansion Pl has built from concept-to-market a robust pipeline of innovation as a platform to drive chem-bio solutions Development investments in Pioxazon to build farmer s confidence on performance in the short term to enable mid term scale and market acceptance Deepening engagement with customers showing some early shoots Building dedicated development and manufacturing capacities; Infrastructure coming to mature phase in Lodi, Italy Actively working on strategic products for long term contracts Margins to normalize once volatility subsides
Page 15
• Top 5 worldwide in AgChem CSM • 70% + revenue from proprietary products PI: Trusted, Resilient and Future - Ready • 6 + decades with Global innovators • Zero conflicts till date • Fully integrated R&D across all disciplines under one roof • Rapid tech adoption • ESG, the way of life • Featured in the S&P Global Sustainability Yearbook 2026 • Never a “ me - too” player • New frontiers Agri | Horticulture | Biologicals | Health Sciences A Trusted Brand & Partnerships Science & Technology ESG Anchored Addressing Emerging Opportunities Successful Product Brands & Services An organization that is committed to excellence in whatever it does . . . known for being a Top wealth creator for over 2 decades . . . 15 AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL A Trusted Brand Successful Product Science & ESG Addressing Emerging & Partnerships Brands & Services Technology Anchored Opportunities 6+ decades Top 5 worldwide Fulg integrated ESG, the way of life Never a me-too player with Global innovators in AgChem CSM R& across all disciplines under one roof Featured in the S&P New frontiers Zero conflicts 70% + revenue Global Agri I Horticulture I till dote from proprietary products Rapid tech Sustainabilitr Biologicals I Health Sciences adoption Yearbook 2026
Page 16
16
Page 17
40+ Countries 10+ Overseas Offices 8 Mfg. Sites 25 Stock Points 4,000+ Employees 100,000+ Retail Points 15,000+ Distributors Dusseldorf Beijing India Tokyo Sao Paulo Amsterdam Milan Our Markets Overseas Offices Mexico City Dubai Seattle St. Louis 2,000+ Contract employees Registered Office Corporate Office R&D Manufacturing Units Depots India Strong understanding of international work culture with 60+ years of deep - rooted relationships Our Global Presence 17 AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL London Almeria
Page 18
18 Partnering Across the Ag - chem Value Chain Non conflicting business model … well respected by Global Innovators as Partner • Objective to be high quality producer • Control all processes that impact quality of the end product • Target driven • Ownership at sub - functional level • Ensure consistent, reliable delivery • Continuous de - bottlenecking • Automation • To set benchmarks • Address at source • Safety first culture • A way of life at PI • Build value for Long - term • Protect and build IP Consistent Quality Cost Competitiveness Speed of execution, delivery Reliable & Adaptable Real - time monitoring & review Customer Needs Business Strategy Development Scale - up Manufacturing Evaluation & Trials Regulatory services & Registrations Marketing & Distribution Discovery AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL 18 Cost Competitiveness Speed of execution, delivery Reliable & Adaptable
Page 19
Technology pioneer with technological and IP based interventions in global contract manufacturing Product portfolio consists of early stage molecules with continued thrust to adapt sustainable practices 8 Manufacturing Sites spread across 150+ Acres equipped with Distributed Control System (DCS ) Capital expenditure underway as per plan with 3 MPPs under construction Extensive experience in handling Hazardous Chemistry with over 130 unit processes Flow Technology Vapor Phase Bio Technology Largest Commercial Scale Reactions Agchem CSM, a global leader, backed by strong technological strengths 19 AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL FINANCIALS / KEY UPDATES / BUSINESS MODEU / ESG / AWARDS Agchem CSM, a global leader, backed by strong technological strengths Technology pioneer with technological and IP based interventions in global contract manufacturing 8 Manufacturing Sites spread across 150+ Acres equipped with Distributed Control System (DCS) Product portfolio consists of early stage molecules with continued thrust to adapt sustainable practices Extensive experience in handling Hazardous Chemistry with over 130 unit processes Capital expenditure underway as per plan with 3 MPPs under construction
Page 20
20 BENEFITS OF CROSS SELLING OPPORTUNITIES PROCURE REPEAT BUSINESS UNDERLYING PRINCIPLES RESPECT & DEVELOP IP REPUTATION OF TRUST & RELIABILITY FORGE RELATIONSHIP Crop Solutions Channel Enablers Digi - tech @Core Farmers Engagement Efficiency Excellence Domestic Business – Brands Strong Partner Having experience more than 6 decades 25+ Global Innovators Strong Pipeline Molecules based on crop solutions and Indian needs • Extension & product development & stewardship (team experience in handling complex new - age premium chemistries) • Strong relationship with stakeholders • Policy level by participation Farmers & Extensive Distribution Network 25 stock points; 15K+ distributors; 100K+ retail points • Crop solution approach focussing farmer & using ICT (Information, Communication and Technology) • Organization structure empowered with digi tech to support and demonstrate value delivery to farmers • Online analytics tools for farmers and employees • I nnovative Ideas and branding for enhancing product life cycle • Experience of successfully managing transition of products from patented to generic • Application services for development & engagement FOCUS ON INNOVATION Evaluation & Trials Regulatory services & Registrations Marketing & Distribution Differentiated Domestic Distribution Model Driven By Unique Solutions through Global Partnerships, Brands Building Capabilities And Market Reach More than 6 decades creating market - leading brands Significant revenue from leading Brands in the market, some brands are more than a decade old AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL FINANCIALS / KEY UPDATES / BUSINESS MOD EU / ESG / AWARDS Differentiated Domestic Distribution Model Driven By Unique Solutions through Global Partnerships, Brands Building Capabilities And Market Reach Strong Partner Having experience more than 6 decades 25+ Global Innovators ----------- Strong Pipeline Molecules based on ...... crop solutions an~ Indian needs Extension & product development & stewardship (team experience in handling complex new-age premium chemistries) Strong relationship with stakeholders Policy level by participation Evaluation & Trials Domestic Business Brands Regulatory services & Registrations Marketing & Distribution Crop Solutions PROCURE REPEAT BUSINESS FOCUS ON INNOVATION UNDERLYING PRINCIPLES RESPECT & DEVELOP IP BENEFITS OF CROSS SELLING OPPORTUNITIES REPUTATION OF TRUST& / RELIABILITY FORGE RELATIONSHIP 0 Digi-tech @Core Engagement Efficiency Excellence Farmers Channel More than 6 decades creating market-leading brands Farmers & Extensive Distribution Network 25 stock points; 15K + distributors; lOOK + Crop solution approach focussing former & using ICT (Information, Communication and Technology) Organization structure empowered with digi tech to support and demonstrate value delivery to farmers Online analytics tools for farmers and employees Innovative Ideas and branding for enhancing product life cycle Experience of successfully managing transition of products from patented to generic Application services for development & engagement • Enablers Significant revenue from leading Brands in the market, some brands are more than a decade old 20
Page 21
Differentiated Portfolio Delivering Value added Crop Solutions to farmers … Strengthening Market Position.. Robust pipeline of 20+ products at different stages of development and registration RICE HORTICULTURE CHILLI WHEAT CORN SUGARCANE Crop Solutions COTTON SOYBEAN 21 AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL Dorito ® Pressedo ® Osheen Ultra ® Claret ® Unique combination of systemic and contact insecticide Solju Gr & Solju SP Kaprigin ® Eketsu 1 st 3 - way Rice Herbicide Pilin ® Bio - fungicide with Novel Mode Of Action Aminogrow Activ Amino acid & Peptides product Campana New systematic insecticide BYROCK ® Alcor ® S ystemic herbicide for management of ALS resistance weeds Comet ® Post emergent herbicide for control of grasses Uranus ® For Mites control Broad spectrum novel insecticide For sucking pest control Unique microbial biofertiliser Broad spectrum insecticide Fungicide Organic Fertiliser Vachan Insecticide for Leps management Fixit ® Herbicide for Rice weeds control Kadett ® Combination Fungicide FY25 FY24 FY26 21 Carvint ® Insecticide with first of its kind technology, belonging to IRAC Gr.34 B road spectrum, contact & preventive fungicide FY27 Insecticides Herbicides Fungicides Biologicals V elchi FINANCIALS / KEY UPDATES / BUSINESS MODEL / ESG / AWARDS Differentiated Portfolio Delivering Value added Crop Solutions to farmers Strengthening Market Position .. FY24 FY25 FY26 FY27 Pressedo Osheen Ultra ---·- Broad spectrum novel For sucking pest Claret Campana"' insecticide control Unique New systematic combination of insecticide Uranus HORTICULTURE systemic and For Mites control Carvint Insecticide with first of its kind technology, belonging to IRAC Gr.34 SOYBEAN contact insecticide & • Eketsu"' 1st 3-way Rice Herbicide Kadett Combination Fungicide Pilin Aminogrow Bio-fungicide with Activ"' Novel Mode Of Amino acid & Action Peptides product Vachan™ Dorito Insecticide for Leps mono ement Broad spectrum insecticide BYROCK Fungicide Kaprigin Organic Fertiliser Solju"'Gr& Solju"'SP Unique microbial biofertiliser I Alcor Comet Systemic herbicide Post emergent for management of herbicide for control ALS resistance of grasses weeds I Fixit Herbicide for Rice weeds control .- Velchi™ Broad spectrum, contact & preventive fungicide Robust pipeline of 20+ products at differen stages of development and registration CHILLI SUGARCANE RICE WHEAT CORN CII C 0 +i :::, 0 C/) CL 0 ... 0
Page 22
Multipronged strategy to sustain the growth momentum backed by multiple growth engines & M&A Prudent capital allocation to ensure the long - term shareholder value creation Deepening our technological capabilities to open new horizons Multiple Growth Engines / Levers De - risk Proces s Digital (A) Innovation Chem - Bio solutions ( B ) New proprietary formulation s ( C ) Expanding beyond Agchem (D) Leveraging manufacturing capabilities in chemistry (A) Information integration (B) Decision tools (C) AI enabling ( A ) Chemistry (B) Building Blocks (C) Process engineering (D) Flow (E) Bio - Catalysis Expansion Creation Segments Operational Excellence Brands Research and process innovation with global partnerships Marketing & Distribution – Global Geographical Expansion Biologicals Tech Platforms PI Health Sciences – CRDMO Specialty & Electronic chemicals Market Inorganic Disruptive Value - added Technologies Product Assets Niche verticals within Pharma/ Specialty chemicals High growth application areas having synergy Build Customer Intimacy Product & Services IP De - risk & Create Inorganic Value creation Organic Grow Smart 22 AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL FINANCIALS / KEY UPDATES / BUSINESS MODEU / ESG / AWARDS Multipronged strategy to sustain the growth momentum backed by multiple growth engines & M&A al Market X Expansion - . Q,, Creation ~ Segments {§} Operational Excellence 0 Brands £ 0 Disruptive Value-added Technologies Product Assets Niche verticals within Pharma/ Specialty chemicals ,£. High growth application areas having synergy Deepening our technological capabilities to open new horizons 0 De-risk (A) Innovation Chem Bio solutions (B) New proprietary formulations (C) Expanding beyond Agchem (D) Leveraging manufacturing capabilities in chemistry O Process {A) Chemistry (B)Building Blocks (C) Process engineering (D)Flow (E) Bio-Catalysis 1;1 Digital {A) Information integration (B) Decision tools (C) Al enabling C, Multiple Growth Engines/ Levers • • Research and process innovation with global partnerships Marketing & Distribution Global Geographical Expansion 0 Biologicals Tech Platforms 0 Pl Health Sciences CRDMO O Specialty & Electronic chemicals @ Prudent capital allocation to ensure the long-term shareholder value creation
Page 23
23 The PI Investment Case: A Proven Growth Engine … Unlocking the Next Era of Growth Demonstrated ability to constantly reinvent itself over 8 Decades Guided by our Values Constantly Differentiating our Business to create Moats with Excellence from Ag distribution to CSM to Innovation in Ag; now to Life Sciences Demonstrated Wealth Creation with Strong Financials Debt free balance sheet, War chest of growth capital Digital Edge From Assets to knowledge, to offer consistency with speed ESG, a Way of Life at PI Top 2 percentile ESG - rated globally, 3 rd consecutive year of S&P CSA yearbook World - class Integrated R&D capabilities from discovery to markets: Science & Technology, our Passion Unique Business Model and Strong Global Relationships with Partners from Innovation to Markets People First Constantly building, acquiring and growing our Human Talent globally 23 AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL Demonstrated ability to constantly reinvent itself over 8 Decades Guided by our Values World-class Integrated R&D capabilities from discovery to markets: Science & Technology, our Passion Constantly Differentiating our Business to create Moats with Excellence from Ag distribution to CSM to Innovation in Ag; now to Life Sciences Digital Edge From Assets to knowledge, to offer consistency with speed Demonstrated Wealth Creation with Strong Financials Debt free balance sheet, War chest of growth capital People First Constantly building, acquiring and growing our Human Talent globally Unique Business Model and Strong Global Relationships with Partners from Innovation to Markets ESG, a Way of Life at Pl Top 2 percentile ESG rated globally, 3rd consecutive year of S&P CSA yearbook
Page 24
Classification | PI Confidential Embedding sustainability into long - term value creation 24 Carbon emissions intensity in terms of revenue from operations (INR million) Water intensity in terms of revenue from operations (INR million) Chemical Oxygen Demand (in MT) Key Highlights* SDG Alignment Environment – Climate change 70% of enrolled youth placed through skill development initiatives 572,000+ healthcare beneficiaries through Mobile Health units and 1 6 7 ,000+ students impacted through various initiatives since FY21 Increased employees’ average training hours per FTE by 13 % from FY2 5 Women in STEM positions increased to 15.5% in FY26 from 13.8% in FY25 800+ acres brought under sustainable agricultural practices by educating farmers about climate - resilient agricultural practices in Q1FY27 Environment – Climate change Environment – Energy management Lost Time Injury Frequency Rate (LTIFR) Environment – Water management 0 for all employees and workers 0 for contractual workers Water intensity increased by ~35% from FY26 Reduced Chemical Oxygen Demand by ~10% from FY26 Key Highlights ~25% renewable energy as a share of total energy consumption Reduced CO 2 emission intensity by 5%+ from FY26 Environmental Social and Governance • For the 2025 edition, more than 8,551 companies were assessed, and only 540 companies secured a place in the Yearbook, including 32 from India. PI Industries is proud to be among the Top 2 percentile of ESG - rated companies worldwide. • PI ranks among the Top 25 companies globally in the chemical sector and is one of only three Indian chemical companies to be included in the 2025 Yearbook. Score 2024 68 2025 77 Featured in the S&P Global Sustainability Yearbook for 3 rd consecutive year PI Industries Limited has been included in the Dow Jones Best in Class (DJ BIC) Indices for Emerging Markets 1.99 2.46 2.34 FY25 FY26 H1FY27 8.2 9.9 13.4 FY25 FY26 H1FY27 23.46 19.67 8.78 FY25 FY26 H1FY27 AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL FINANCIALS / KEY UPDATES / BUSINESS MODEL / ESG / AWARDS Embedding sustainability into long-term value creation Environmental Social and Governance ■-. SDG Alignment Environment Climate change Environment Climate change Environment Energy management Environment Water management LostTime Injury Frequency Rate (L TIFR) Key Highlights* Reduced CO, emission intensity by 5%+ from FY26 Reduced Chemical Oxygen Demand by -10% from FY26 -25% renewable energy as a share of total energy consumption Water intensity increased by -35% from FY26 0 for all employees and workers 0 for contractual workers II II 11 11 Key Highlights Increased employees average training hours per FTE by 13% from FY25 Women in STEM positions increased to 15.5% in FY26 from 73.8% in FY25 800+ acres brought under sustainable agricultural practices by educating farmers about climate- resilient agricultural practices in QlFY27 70% of enrolled youth placed through skill development initiatives 572,000+ healthcare beneficiaries through Mobile Health units and 167,000+ students impacted through various initiatives since FY2l Featured in the S&P Global Sustainability Yearbook for 3rd consecutive year Pl Industries Limited has been included in the Dow Jones Best in Class (DJ BIC) Indices for Emerging Markets 2024 2025 Score 68 77 Pl ranks among the Top 25 companies globally in the chemical sector and is one of only three Indian chemical companies to be included in the 2025 Yearbook. For the 2025 edition, more than 8,551 companies were assessed, and only 540 companies secured a place in the Yearbook, including 32 from India. Pl Industries is proud to be among the Top 2 percentile of ESG-rated companies worldwide.
Page 25
Our commitment to Community... HEALTH & HYGIENE WOMEN EMPOWERMENT EDUCATION & SKILL DEVELOPMENT ENVIRONMENT SUSTAINABILITY 66 villages, Shvastha Seva 45,800+ beneficiaries in Q2FY27 80 rural villages active 8,000+ women benefited ~25% income increase via programs 2,000+ farmers reached in Q2FY27 ~800+ acres covered in Q2FY27 6,500+ trees restored & planted in Q2FY27 Building strong, healthy communities across India through targeted CSR programs 25 AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL 275+ youth skilled till Q2FY27 7,000+ students supported with education material
Page 26
Three Sites Unique Achievement - Sword of Honour 26 FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL AWARDS Jambusar • Panoli • Udaipur - achieved 5 - star rating in the British Safety Council Five - Star Audit A proud milestone in our pursuit of safety excellence. Jambusar Panoli Udaipur (R&D)
Page 27
27 Thank You